- Home
- AAME vs BTAI Comparison
AAME vs BTAI Comparison
Compare AAME & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AAME | BTAI |
|---|---|---|
| Founded | 1968 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.6M | 49.2M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | AAME | BTAI |
|---|---|---|
| Price | $2.93 | $2.01 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.80 |
| AVG Volume (30 Days) | 31.3K | ★ 470.3K |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | ★ 0.67% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $208,218,000.00 | $752,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $441.98 |
| P/E Ratio | $13.00 | ★ N/A |
| Revenue Growth | ★ 11.99 | N/A |
| 52 Week Low | $1.25 | $1.17 |
| 52 Week High | $3.71 | $9.26 |
Technical Indicators
Market Signals| Indicator | AAME | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 57.76 | 57.65 |
| Support Level | $2.59 | $1.50 |
| Resistance Level | $3.15 | $1.89 |
| Average True Range (ATR) | 0.28 | 0.12 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 65.80 | 81.45 |
Price Performance
Historical ComparisonAbout AAME Atlantic American Corporation
Atlantic American Corp operates in specialty markets within the life and health and property and casualty insurance industries. The company has two segments: American Southern, It provides property and casualty insurance including bodily injury and property damage liability coverage, uninsured motorist coverage, and physical damage coverage for commercial accounts, and Bankers Fidelity, the company's life and health operations offer a variety of life and supplemental health products including ordinary and term life insurance, Medicare supplement, and other health insurance.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.